New Bridge Venture Aligns With Takeda Externalization Strategy
A new collaborative academic-industry medicines development venture involving Takeda has started operations in the US, aiming to smooth and speed the passage of basic research projects through clinical trials and eventually to the market.
You may also be interested in...
Takeda’s CEO says the company is continuing to deliver on its turnaround plan after a stronger first half, with Entyvio providing much of the momentum for the underlying growth and a brighter full-term outlook.
As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.
While Astellas, like many other large pharma firms globally, is pursuing the adoption of digital technologies across multiple disciplines, it is aiming to keep patients at the center of its initiatives and also sees a strong need for the "best mix" of the human touch and technology.